Robeco Institutional Asset Management B.V. Decreases Stake in Boston Scientific Corporation $BSX

Robeco Institutional Asset Management B.V. cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 0.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,118,868 shares of the medical equipment provider’s stock after selling 26,909 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.21% of Boston Scientific worth $304,495,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Financial Perspectives Inc raised its position in shares of Boston Scientific by 1.5% in the third quarter. Financial Perspectives Inc now owns 136,167 shares of the medical equipment provider’s stock valued at $13,294,000 after purchasing an additional 2,017 shares during the period. KG&L Capital Management LLC grew its stake in Boston Scientific by 122.4% in the 3rd quarter. KG&L Capital Management LLC now owns 4,170 shares of the medical equipment provider’s stock valued at $407,000 after buying an additional 2,295 shares in the last quarter. D.A. Davidson & CO. raised its holdings in Boston Scientific by 20.8% during the 3rd quarter. D.A. Davidson & CO. now owns 15,260 shares of the medical equipment provider’s stock valued at $1,490,000 after acquiring an additional 2,628 shares during the period. CWA Asset Management Group LLC lifted its position in shares of Boston Scientific by 3.1% during the third quarter. CWA Asset Management Group LLC now owns 11,558 shares of the medical equipment provider’s stock worth $1,128,000 after acquiring an additional 349 shares in the last quarter. Finally, Daymark Wealth Partners LLC boosted its holdings in shares of Boston Scientific by 3.1% in the third quarter. Daymark Wealth Partners LLC now owns 4,971 shares of the medical equipment provider’s stock worth $485,000 after acquiring an additional 151 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

NYSE BSX opened at $95.54 on Tuesday. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company has a fifty day moving average of $97.78 and a 200-day moving average of $100.87. The company has a market capitalization of $141.63 billion, a P/E ratio of 51.09, a P/E/G ratio of 1.68 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter last year, the business posted $0.63 earnings per share. The company’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BSX shares. Barclays boosted their price objective on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, Morgan Stanley increased their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $124.95.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 93,095 shares of company stock worth $9,305,450 in the last quarter. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.